Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following two offers if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
JOIN THE CLUB
Canadian Insider Ad-Free
$49/ year*
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
GO AD-FREE

* Price is subject to applicable taxes. Money back guarantee: For bona fide Ad-Free or Canadian Insider Club subscribers, if you downgrade to Basic or cancel with-in 10 days of first subscribing, we will refund your payment upon request. Immediately after downgrading or cancelling, using the same email that is associated with your account, request a refund via our Contact Us form at the bottom of the page. We will only consider one refund request per household or organization. We cannot accommodate refund requests where an account holder has not provided verifiable address and billing information.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Log in or join to add this stock to your watch list.
Feb 14, 2019 02:00 am ET
Breathtec Announces Name Change to Algernon Pharmaceuticals
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”) is pleased to announce that as a result of the strength of the data from its Nash Pharmaceuticals pre-clinical research program, it will...
Feb 13, 2019 02:00 am ET
Nash Pharmaceuticals to Present Data on Its Inflammatory Bowel Disease Research Program at The Digestive Disease Week Annual Conference
Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that it has been accepted to present its pre-clinical...
Jan 31, 2019 02:00 am ET
Nash Pharmaceuticals to Present Pre-Clinical Data on Non-Alcoholic Fatty Liver Disease at 2nd Global NASH Congress in London, UK
Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (the “Company” or “Nash Pharma”) is pleased to announce that it will be presenting its pre-clinical data on its non-alcoholic steatohepatitis...
Jan 21, 2019 02:00 am ET
Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound In Second Pre-Clinical Study For Non-Alcoholic Fatty Liver Disease
Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that its lead compound for non-alcoholic...
Jan 14, 2019 02:00 am ET
Nash Pharmaceuticals Announces Positive Pre-Clinical Results From a Second Study for Chronic Kidney Disease as well as 2 Additional Lead Targets
Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that in a new recent in vivo animal study for Chronic...
Jan 10, 2019 02:00 am ET
Shareholder Press Release
Breathtec Biomedical Inc. (CSE: BTH) advises that Kulwant Malhi (the “Acquiror”), through a series of securities acquisition transactions in the share capital of Breathtec BioMedical Inc. (the “Issuer”), and immediately after these securities...
Dec 03, 2018 02:00 am ET
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease
Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that in a recent in vivo animal study for Crohn’s...
Nov 19, 2018 02:00 am ET
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-135 in Chronic Kidney Disease
Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCD) (the “Company” or “Nash Pharma”) is pleased to announce that one of its lead compounds for chronic kidney...
Nov 13, 2018 02:00 am ET
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease
Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that one of its lead compounds for Inflammatory Bowel...
Nov 05, 2018 02:00 am ET
Breathtec Provides Update on FAIMS Breathalyzer Development Program
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to report on the development of its Breathtec Disease Detection Breathalyzer (“V3”) prototype based on the  FAIMS (field asymmetric waveform...
Nov 01, 2018 03:00 am ET
Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease
Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that its lead compound for non-alcoholic...
Oct 24, 2018 03:00 am ET
Breathtec Announces Closing of Private Placement
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”) is pleased to announce that it has closed its previously announced non-brokered private placement of 2,083,334 units (the “Units”) at a...
Oct 22, 2018 03:00 am ET
Breathtec Announces Acquisition of Nash Pharmaceuticals
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”) is pleased to announce that further to its press release of October 9, 2018, it has completed the acquisition (the “Transaction”) of all...
Oct 16, 2018 04:22 am ET
Breathtec to Complete Share Consolidation
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to announce that further to its news release dated August 2, 2018, the Company will consolidate its common shares on a two (2) for one (1)...
Oct 09, 2018 03:00 am ET
Breathtec Announces Signing of Definitive Agreement to Acquire Nash Pharmaceuticals
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”) is pleased to announce that further to its press release of August 2, 2018, it has signed a share exchange agreement dated October 5,...
Sep 14, 2018 03:00 am ET
Breathtec to Participate in the 2nd Annual RAI$E on the WEST COAST Small-Cap Investing Conference in Vancouver, BC, September 14-15
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) will be presenting at the 2nd Annual RAI$E on the WEST COAST Small-Cap Investing Conference in Vancouver, BC, September 14-15. We will be in Meeting...
Sep 13, 2018 03:00 am ET
Breathtec Provides Nash Pharmaceuticals’ Plans for Next Year
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to provide details on Nash Pharmaceutical’s (“Nash Pharma”) plans for the next 12 month period. Breathtec recently announced that it has...
Aug 02, 2018 03:00 am ET
Breathtec to Open New Drug Development Division, Signs LOI to acquire 100% of Clinical Stage Nash Pharmaceuticals Inc.
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to announce that it will be opening a new drug development division and has signed a Letter of Intent (“LOI”) to acquire 100% of the shares...
Mar 01, 2018 04:00 am ET
Breathtec Biomedical Announces Appointment of CEO
VANCOUVER, British Columbia, March 01, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE:BTH) (CNSX:BTH) (FRANKFURT:BTI) (OTCQB:BTHCF) (the “Company”) is pleased to announce the appointment of Christopher J. Moreau as Chief Executive Officer effective March 1, 2018.
Jan 08, 2018 05:43 pm ET
Breathtec Biomedical Unaware of Any Material Change
VANCOUVER, British Columbia, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical, Inc. (CSE:BTH) (OTCQB:BTHCF) (the “Company” or “Breathtec”) - at the request of the Investment Industry Regulatory Organization of Canada, Breathtec confirms that the Company management is unaware of...
Nov 14, 2017 09:46 am ET
IIROC Trade Resumption - BTH
VANCOUVER, Nov. 14, 2017 /CNW/ - Trading resumes in:
Nov 14, 2017 04:48 am ET
IIROC Trading Halt - BTH
VANCOUVER, Nov. 14, 2017 /CNW/ - The following issues have been halted by IIROC:
Sep 20, 2017 01:05 pm ET
Breathtec Biomedical Announces Resignation of Chief Executive Officer
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company") announces that effective immediately, Guy La Torre has resigned as Director and Chief Executive Officer ("CEO") of the Company to pursue other ventures. The Company wishes Guy the best with his future endeavours. An interim CEO will be appointed in due course.
May 18, 2017 05:00 am ET
Breathtec BioMedical to Investigate Zika Virus Airborne Disease Detection
Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative breath analysis devices for the early detection of infectious and life threatening diseases, wishes to address recent corporate events and to provide an update regarding its immediate outlook and future plans.
Mar 17, 2017 05:00 am ET
Breathtec BioMedical CTO Delivers Presentation to International Science Community
Breathtec BioMedical, Inc. (CSE: BTH.CN) (CNSX: BTH) (CSE: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases is pleased to report that the Company's previously announced invitation to speak at the 2017 Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy (PittCon) was a notable success.
Mar 01, 2017 03:00 am ET
Breathtec Biomedical Provides Corporate Overview
Breathtec BioMedical, Inc. (CSE: BTH.CN) (CNSX: BTH) (CSE: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases wishes to address recent corporate events and to provide an update regarding its immediate outlook and future plans.
Dec 19, 2016 04:00 am ET
Breathtec BioMedical Attends BC Ministers Trade Mission to Israel and Announces Approval of Clinical Trials
Breathtec BioMedical, Inc. (CSE: BTH.CN) (CNSX: BTH) (CSE: BTH) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases is pleased to announce its Lead Engineer, Dr. Raj Attariwala, attended the British Columbia (BC) Ministers Trade Mission to Israel on behalf of Breathtec Biomedical November 13-17, 2016.
Oct 18, 2016 01:08 pm ET
Breathtec BioMedical Announces Private Placement
Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases, is pleased to announce that it intends to complete a non-brokered private placement offering of up to 13,333,333 units (the "Units") at a price of $0.075 per Unit for gross proceeds of up to $1,000,000 (the "Offering"). Each Unit will consist of one common share in the capital
Oct 17, 2016 04:30 am ET
Breathtec BioMedical Provides Corporate Overview
Breathtec BioMedical, Inc. (CSE: BTH.CN) (CNSX: BTH) (CSE: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases wishes to address recent corporate events and to provide an update regarding its immediate outlook and future plans.
Oct 03, 2016 04:30 am ET
Breathtec BioMedical Presents Point-of-Care Strategy at International Breath Research Conference
Breathtec BioMedical, Inc. (CSE: BTH.CN) (CNSX: BTH) (CSE: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases is pleased to report that the Company's previously announced 2016 IABR Breath Summit participation and sponsorship was a notable success.
Sep 27, 2016 04:30 am ET
Breathtec Biomedical Engages DTG Partners to Advance Product Commercialization
Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases is pleased to announce the engagement of DTG Partners Consultants (www.dtgpartners.ca) to advance the efforts towards product commercialization.
Sep 08, 2016 04:30 am ET
Breathtec BioMedical to Present at 2016 International Association of Breath Research
Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases is pleased to announce that Chief Technology Officer Dr. Michael Costanzo will be making a presentation regarding the development of the Company's technology at the 2016 IABR Breath Summit scheduled for September 14 to 16 in Zurich, Switzerland.
Jun 28, 2016 03:00 am ET
Breathtec Biomedical Announces Plans for Breath Analysis Clinical Trials at Canadian Tech Facility
Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases, is holding a press conference today to announce plans for the commencement of the company's clinical trial program at Innovation Boulevard located in Surrey, British Columbia.
Jun 20, 2016 03:00 am ET
Breathtec BioMedical Appoints Guy LaTorre as Chief Executive Officer
Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infections and life threatening diseases, is pleased to announce the appointment of Mr. Guy LaTorre as Chief Executive Officer of the Company. Mr. LaTorre was previously an advisor to the Company on product development and licensing matters.
May 24, 2016 04:00 am ET
Breathtec Biomedical Closes License of NA-NOSE Technology for Disease Detection
Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases is pleased to announce that further to its press release of April 13, 2016, it has now issued 1,000,000 common shares of the Company ("Shares") to Technion Research and Development Foundation Ltd., an Israeli private company and wholly-owned subsidiary of the Technion -- Israel
May 19, 2016 04:30 am ET
Breathtec Biomedical Announces Trading on OTCQB
Breathtec Biomedical, Inc. (CNSX: BTH) (CSE: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases is pleased to announce that its common shares are now trading on the OTCQB® Venture Market in the United States under the symbol "BTHCF."
Apr 19, 2016 04:00 am ET
Breathtec Biomedical Announces Prof. Hossam Haick as Consultant
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTC PINK: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases is pleased to announce that Professor Hossam Haick of Technion University and the developer of the NA-NOSE disease detection sensors has joined Breathtec Biomedical as consultant. Prof. Haick will guide the company's development of the NA-NOSE disease detection system and design the
Apr 12, 2016 11:30 pm ET
Breathtec Biomedical In-Licenses Advanced Stage Breath Analysis Technology
Breathtec Biomedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTC PINK: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases, is pleased to announce the signing of a license agreement dated as of April 11, 2016 (the "License Agreement") between the Company and Technion Research and Development Foundation Ltd., an Israeli private company and wholly-owned subsidiary of the Technion - Israel Institute of Technology